# SLC16A1

## Overview
The SLC16A1 gene encodes the protein monocarboxylate transporter 1 (MCT1), a member of the solute carrier family 16. MCT1 is a transmembrane protein that plays a crucial role in the proton-linked transport of monocarboxylates, such as lactate, pyruvate, and ketone bodies, across the plasma membrane. This transporter is part of the major facilitator superfamily (MFS) and is characterized by its 12 transmembrane helices, which facilitate its function in various tissues, including skeletal muscle, heart, and brain (Halestrap2013The; Felmlee2020Monocarboxylate). MCT1 is essential for maintaining cellular energy homeostasis and is involved in critical physiological processes such as glycolysis and neuronal energy metabolism (Halestrap2013The; AlKhawaga2019A). The protein's activity is modulated through interactions with glycoproteins like basigin, which are necessary for its proper localization and function (Halestrap2013The). Alterations in the expression or function of SLC16A1 have been implicated in various clinical conditions, including metabolic disorders and cancer (Demirbilek2019Ion; Zhang2021High).

## Structure
The SLC16A1 gene encodes the monocarboxylate transporter 1 (MCT1), a protein involved in the proton-linked transport of monocarboxylates such as L-lactate, pyruvate, and ketone bodies across the plasma membrane. MCT1 is part of the major facilitator superfamily (MFS) and is characterized by 12 transmembrane helices (TMs) with intracellular C- and N-termini, and a large cytosolic loop between TMs 6 and 7 (Halestrap2013The; Halestrap2011The). The protein's structure has been modeled in both 'closed' and 'open' conformations, with the closed conformation having a cytosolic substrate binding site and the open conformation having an extracellular substrate binding site (Halestrap2013The).

Key residues such as lysine (K38), aspartate (D302), and arginine (R306) are crucial for MCT1's transport activity, with K38 playing a significant role in the substrate-binding channel (Halestrap2013The; Wilson2009Studies). MCT1 requires association with glycosylated ancillary proteins, such as basigin or embigin, for correct translocation to the plasma membrane, although MCT1 itself is not glycosylated (Halestrap2011The; Halestrap2013The). The protein can form dimers with basigin, which is important for its function (Halestrap2013The). The structural dynamics of MCT1 involve a 'rocker switch' mechanism, where the N- and C-terminal halves rock back and forth to facilitate substrate translocation (Wilson2009Studies).

## Function
The SLC16A1 gene encodes the monocarboxylate transporter 1 (MCT1), which is integral to the transport of monocarboxylates such as lactate, pyruvate, and ketone bodies across cell membranes. MCT1 operates through a proton-linked transport mechanism, where a proton binds first, followed by the lactate anion, facilitating their translocation across the membrane (Halestrap2013The). This process is crucial for maintaining cellular energy homeostasis, particularly in tissues with high metabolic activity like skeletal muscle, heart, and brain, where lactate serves as an important respiratory substrate (Halestrap2013The).

MCT1 is ubiquitously expressed in various tissues and plays a significant role in the glycolysis cycle by transporting lactate and pyruvate, products of glycolysis, across the plasma membrane (Felmlee2020Monocarboxylate). In the brain, MCT1 is involved in delivering lactate to neuronal cells, which is essential for proper neuronal function and energy metabolism, especially under conditions of increased energy demand (AlKhawaga2019A). MCT1 also contributes to maintaining intracellular pH by facilitating the efflux of lactate, which is particularly important in tissues with high glycolytic activity (Halestrap2013The). Its activity is enhanced by interaction with intracellular carbonic anhydrase II, which may provide a 'proton-collecting antenna' (Halestrap2013The).

## Clinical Significance
Mutations and altered expression of the SLC16A1 gene, which encodes the monocarboxylate transporter 1 (MCT1), are associated with several clinical conditions. Dominant activating mutations in the promoter region of SLC16A1 can lead to exercise-induced hyperinsulinemic hypoglycemia. This condition is characterized by inappropriate insulin secretion during anaerobic exercise due to increased uptake of lactate and pyruvate in pancreatic beta-cells, resulting in hypoglycemia (Felmlee2020Monocarboxylate; Demirbilek2019Ion).

MCT1 deficiency, caused by inactivating mutations in SLC16A1, is linked to recurrent ketoacidosis. This condition is marked by severe metabolic acidosis and massive urinary excretion of ketone bodies, often triggered by fasting or infections. Patients with MCT1 deficiency may also experience developmental delays and neurological issues (van2014Monocarboxylate; AlKhawaga2019A).

In cancer, SLC16A1 is overexpressed in various tumors, including urological cancers and melanoma. High expression levels are associated with poor prognosis, increased tumor aggressiveness, and immune system interactions. SLC16A1's role in cancer metabolism involves maintaining glycolysis efficiency and promoting tumor cell invasion (Zhang2021High; Xie2021Solute).

## Interactions
SLC16A1, also known as monocarboxylate transporter 1 (MCT1), is involved in several protein-protein interactions crucial for its function. MCT1 requires association with glycoproteins such as basigin (CD147) or embigin for correct plasma membrane expression and activity. These interactions are essential for the proper functioning of MCT1, as they facilitate its transport activity across the plasma membrane (Halestrap2013The; Meredith2008The). Basigin, in particular, acts as a chaperone protein, ensuring the correct localization and function of MCT1. The interaction between MCT1 and basigin is critical for the expression and activity of MCT1, as demonstrated by disrupted expression in basigin knockout models (Halestrap2013The).

MCT1 also forms stable associations with chaperone proteins like basigin and embigin, as confirmed by structural predictions using AlphaFold-Multimer, which achieved high-confidence structures for these heterodimers (Frommelt2024The). Additionally, MCT1 interacts with intracellular carbonic anhydrase II, enhancing its activity, although this interaction occurs independently of the enzyme's catalytic activity (Halestrap2013The). These interactions highlight the complex network of protein associations that regulate the function and expression of SLC16A1.


## References


[1. (Meredith2008The) D. Meredith and H. C. Christian. The slc16 monocaboxylate transporter family. Xenobiotica, 38(7–8):1072–1106, August 2008. URL: http://dx.doi.org/10.1080/00498250802010868, doi:10.1080/00498250802010868. This article has 81 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/00498250802010868)

[2. (Halestrap2013The) Andrew P. Halestrap. The slc16 gene family – structure, role and regulation in health and disease. Molecular Aspects of Medicine, 34(2–3):337–349, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.05.003, doi:10.1016/j.mam.2012.05.003. This article has 519 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.05.003)

[3. (Halestrap2011The) Andrew P. Halestrap. The monocarboxylate transporter family—structure and functional characterization. IUBMB Life, 64(1):1–9, November 2011. URL: http://dx.doi.org/10.1002/iub.573, doi:10.1002/iub.573. This article has 529 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/iub.573)

[4. (Zhang2021High) Ling Zhang, Zheng-Shuai Song, Zhi-Shun Wang, Yong-Lian Guo, Chang-Geng Xu, and Hao Shen. High expression of slc16a1 as a biomarker to predict poor prognosis of urological cancers. Frontiers in Oncology, September 2021. URL: http://dx.doi.org/10.3389/fonc.2021.706883, doi:10.3389/fonc.2021.706883. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.706883)

[5. (Felmlee2020Monocarboxylate) Melanie A. Felmlee, Robert S. Jones, Vivian Rodriguez-Cruz, Kristin E. Follman, and Marilyn E. Morris. Monocarboxylate transporters (slc16): function, regulation, and role in health and disease. Pharmacological Reviews, 72(2):466–485, March 2020. URL: http://dx.doi.org/10.1124/pr.119.018762, doi:10.1124/pr.119.018762. This article has 225 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1124/pr.119.018762)

[6. (Demirbilek2019Ion) Huseyin Demirbilek, Sonya Galcheva, Dogus Vuralli, Sara Al-Khawaga, and Khalid Hussain. Ion transporters, channelopathies, and glucose disorders. International Journal of Molecular Sciences, 20(10):2590, May 2019. URL: http://dx.doi.org/10.3390/ijms20102590, doi:10.3390/ijms20102590. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms20102590)

[7. (AlKhawaga2019A) Sara Al-Khawaga, Jehan AlRayahi, Faiyaz Khan, Saras Saraswathi, Reem Hasnah, Basma Haris, Idris Mohammed, Essam M. Abdelalim, and Khalid Hussain. A slc16a1 mutation in an infant with ketoacidosis and neuroimaging assessment: expanding the clinical spectrum of mct1 deficiency. Frontiers in Pediatrics, July 2019. URL: http://dx.doi.org/10.3389/fped.2019.00299, doi:10.3389/fped.2019.00299. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fped.2019.00299)

8. (Frommelt2024The) The solute carrier superfamily interactome. This article has 0 citations.

[9. (van2014Monocarboxylate) Peter M. van Hasselt, Sacha Ferdinandusse, Glen R. Monroe, Jos P.N. Ruiter, Marjolein Turkenburg, Maartje J. Geerlings, Karen Duran, Magdalena Harakalova, Bert van der Zwaag, Ardeshir A. Monavari, Ilyas Okur, Mark J. Sharrard, Maureen Cleary, Nuala O’Connell, Valerie Walker, M. Estela Rubio-Gozalbo, Maaike C. de Vries, Gepke Visser, Roderick H.J. Houwen, Jasper J. van der Smagt, Nanda M. Verhoeven-Duif, Ronald J.A. Wanders, and Gijs van Haaften. Monocarboxylate transporter 1 deficiency and ketone utilization. New England Journal of Medicine, 371(20):1900–1907, November 2014. URL: http://dx.doi.org/10.1056/nejmoa1407778, doi:10.1056/nejmoa1407778. This article has 92 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1056/nejmoa1407778)

[10. (Wilson2009Studies) Marieangela C. Wilson, David Meredith, Chotirote Bunnun, Richard B. Sessions, and Andrew P. Halestrap. Studies on the dids-binding site of monocarboxylate transporter 1 suggest a homology model of the open conformation and a plausible translocation cycle. Journal of Biological Chemistry, 284(30):20011–20021, July 2009. URL: http://dx.doi.org/10.1074/jbc.m109.014217, doi:10.1074/jbc.m109.014217. This article has 83 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m109.014217)

[11. (Xie2021Solute) Jiaheng Xie, Zhechen Zhu, Yuan Cao, Shujie Ruan, Ming Wang, and Jingping Shi. Solute carrier transporter superfamily member slc16a1 is a potential prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma. Channels, 15(1):483–495, January 2021. URL: http://dx.doi.org/10.1080/19336950.2021.1953322, doi:10.1080/19336950.2021.1953322. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/19336950.2021.1953322)